Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

被引：283

作者：

Byrski, T. ^{[2
]}

Huzarski, T. ^{[2
]}

Dent, R. ^{[3
]}

Gronwald, J. ^{[2
]}

Zuziak, D. ^{[4
]}

Cybulski, C. ^{[2
]}

Kladny, J. ^{[2
]}

Gorski, B. ^{[2
]}

Lubinski, J. ^{[2
]}

Narod, S. A. ^{[1
]}

机构：

[1] Womens Coll, Res Inst, Toronto, ON M5G 1N8, Canada

[2] Pomeranian Med Univ, Szczecin, Poland

[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[4] Reg Oncol Ctr, Bielsko Biala, Poland

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2009年 / 115卷 / 02期

关键词：

Cisplatin; BRCA1; BRCA2; MUTATIONS; CHEMOTHERAPY; PACLITAXEL; RESISTANCE; SURVIVAL; GROWTH; TUMORS; AGE;

D O I：

10.1007/s10549-008-0128-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy. Methods The excised breast tissue and lymph nodes were examined for the presence of residual disease. Results Pathologic complete response was observed in nine patients (90%). Conclusions Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.

引用

页码：359 / 363

页数：5

共 20 条

[1] The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].

Bhattacharyya, A ;

Ear, US ;

Koller, BH ;

Weichselbaum, RR ;

Bishop, DK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903

[2] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

[3] Improved survival in women with BRCA-associated ovarian carcinoma [J].

Cass, I ;

Baldwin, RL ;

Varkey, T ;

Moslehi, R ;

Narod, SA ;

Karlan, BY .

CANCER, 2003, 97 (09) :2187-2195

[4] BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance [J].

Chabalier, C. ;

Lamare, C. ;

Racca, C. ;

Privat, M. ;

Valette, A. ;

Larminat, F. .

CELL CYCLE, 2006, 5 (09) :1001-1007

[5] Platinum-based chemotherapy in metastatic breast cancer: current status [J].

Decatris, MP ;

Sundar, S ;

O'Byrne, KJ .

CANCER TREATMENT REVIEWS, 2004, 30 (01) :53-81

[6] Estrogen receptor status in BRCA1- and BRCA2-related breast cancer:: The influence of age, grade, and histological type [J].

Foulkes, WD ;

Metcalfe, K ;

Sun, P ;

Hanna, WM ;

Lynch, HT ;

Ghadirian, P ;

Tung, N ;

Olopade, OI ;

Weber, BL ;

McLennan, J ;

Olivotto, IA ;

Bégin, LR ;

Narod, SA .

CLINICAL CANCER RESEARCH, 2004, 10 (06) :2029-2034

[7] A high proportion of founder BRCA1 mutations in Polish breast cancer families [J].

Górski, B ;

Jakubowska, A ;

Huzarski, T ;

Byrski, T ;

Gronwald, J ;

Grzybowska, E ;

Mackiewicz, A ;

Stawicka, M ;

Bebenek, M ;

Sorokin, D ;

Fiszer-Maliszewska, L ;

Haus, O ;

Janiszewska, H ;

Niepsuj, S ;

Gózdz, S ;

Zaremba, L ;

Posmyk, M ;

Pluzanska, M ;

Kilar, E ;

Czudowska, D ;

Wasko, B ;

Miturski, R ;

Kowalczyk, JR ;

Urbanski, K ;

Szwiec, M ;

Koc, J ;

Debniak, B ;

Rozmiarek, A ;

Debniak, T ;

Cybulski, C ;

Kowalska, E ;

Toloczko-Grabarek, A ;

Zajaczek, S ;

Menkiszak, J ;

Medrek, K ;

Masojc, B ;

Mierzejewski, M ;

Narod, SA ;

Lubinski, J .

INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (05) :683-686

[8] Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease [J].

Gralow, Julie R. ;

Burstein, Harold J. ;

Wood, William ;

Hortobagyi, Gabriel N. ;

Gianni, Luca ;

Von Minckwitz, Gunter ;

Buzdar, Aman U. ;

Smith, Ian E. ;

Symmans, William F. ;

Singh, Baljit ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :814-819

[9] The role of BRCA1 in the cellular response to chemotherapy [J].

Kennedy, RD ;

Quinn, JE ;

Mullan, PB ;

Johnston, PG ;

Harkin, DP .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (22) :1659-1668

[10] Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations [J].

Lakhani, SR ;

Jacquemier, J ;

Sloane, JP ;

Gusterson, BA ;

Anderson, TJ ;

van de Vijver, MJ ;

Farid, LM ;

Venter, D ;

Antoniou, A ;

Storfer-Isser, A ;

Smyth, E ;

Steel, CM ;

Haites, N ;

Scott, RJ ;

Goldgar, D ;

Neuhausen, S ;

Daly, PA ;

Ormiston, W ;

McManus, R ;

Scherneck, S ;

Ponder, BAJ ;

Ford, D ;

Peto, J ;

Stoppa-Lyonnet, D ;

Bignon, YJ ;

Struewing, JP ;

Spurr, NK ;

Bishop, DT ;

Klijn, JGM ;

Devilee, P ;

Cornelisse, CJ ;

Lasset, C ;

Lenoir, G ;

Barkardottir, RB ;

Egilsson, V ;

Hamann, U ;

Chang-Claude, J ;

Sobol, H ;

Weber, B ;

Stratton, MR ;

Easton, DF .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (15) :1138-1145

← 1 2 →